Immatics
![Moderna has partnered with Immatics to develop mRNA-based cancer vaccines, bispecifics and cell therapies. The deal includes a $120 million upfront payment and up to $1.7 billion in milestones.](https://pharmtales.com/wp-content/uploads/2023/09/Moderna-expands-cancer-vaccine-portfolio-with-Immatics-deal-worth-up-to-1.7B.jpg)
Moderna expands cancer vaccine portfolio with Immatics deal worth up to $1.7B
Anika Sharma
Moderna is intensifying its focus on cancer vaccines and cell therapies through a newly announced research partnership with Immatics, a ...
Moderna is intensifying its focus on cancer vaccines and cell therapies through a newly announced research partnership with Immatics, a ...